End repair driven secondary in-vitro transcription machine for single-molecule detection of alkaline phosphatase level in human cancer

Through terminal repair-driven secondary in vitro transcription machine combined with T7 transcription amplification technology, high sensitivity detection of ALP is achieved, solving the complex and time-consuming problem of detection in the prior art, and realizing the single-molecule level of human cancer in humans Fast and sensitive detection of ALP levels.

CN118957068APending Publication Date: 2024-11-15SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411118742.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing ALP detection methods are complex, time-consuming and insufficient sensitivity, making it difficult to achieve high sensitivity detection under simple and fast conditions, especially the detection of alkaline phosphatase levels in human cancer at the single molecule level.

Method used

Using a secondary in vitro transcription machine driven by end repair, using ALP catalytic dephosphorylation and T7 transcription amplification technology, combined with hairpin probes and signal probes, the fluorescence signal is released through the secondary in vitro transcription cascade driven by end repair, to achieve the High sensitivity detection to ALP.

Benefits of technology

The detection limit of ALP in vitro reaches 7.93×10-8U/μL and 1 cell in vivo is achieved. It has high signal-to-noise ratio and selectivity, and can be performed isothermal in a test tube without cumbersome procedures and high sample consumption. Suitable for evaluating kinetic parameters and screening inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957068A_ABST
    Figure CN118957068A_ABST
Patent Text Reader

Abstract

The invention discloses a terminal repair driven secondary in-vitro transcription machine for single-molecule detection of alkaline phosphatase level in human cancer, and belongs to the technical field of biological analysis. According to the method, HP1 and a sample solution are mixed to remove phosphate groups in the HP1 catalyzed by ALP, after dephosphorylation, HP2, a signal probe, T7RNA polymerase, TaqDNA ligase, DSN, NTPs and RNase are added for incubation, and then the alkaline phosphatase level in a sample is detected; based on high specificity of ALP catalytic dephosphoric acid, high amplification efficiency of secondary in-vitro transcription cascade and high signal-to-noise ratio of single molecule detection, the method has good specificity and ultrahigh sensitivity. The method can be used for evaluating kinetic parameters, screening potential inhibitors and quantifying ALP levels in various cancer cells and human serum, and the detection limits of the method on ALP can reach 7.93 * 10 <-8 > U / mu L in vitro and 1 cell in vivo respectively.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an end-repair driven secondary in vitro transcription machine for single molecule detection of alkaline phosphatase level in human cancer, belonging to the technical field of biological analysis. Background Art

[0002] Alkaline phosphatase (ALP) is an important monophosphohydrolase that is widely distributed in human tissues at different levels. ALP can catalyze the hydrolysis of phosphate groups in nucleic acids, proteins, and carbohydrates, and plays a key regulatory role in a variety of biological processes (such as cellular metabolism, molecular transport, and signal transduction). The average level of ALP in the serum of normal adults is 40-150U / L, and abnormal ALP levels may induce a variety of human diseases and cancers. Low levels of ALP are associated with various metabolic disorders, including leukemia, aplastic anemia, and Wilson's disease. In contrast, high levels of ALP are associated with bone diseases (such as osteomalacia and osteoblastic tumors) and cancers (such as oral cancer, breast cancer, prostate cancer, and liver cancer). In addition, due to its high catalytic activity and broad substrate specificity, ALP is often used as a marker tracer in molecular monitoring, histochemical staining, and gene expression analysis. Therefore, the specific and highly sensitive detection of ALP is of great significance for biomedical research and cancer diagnosis and treatment.

[0003] T7 in vitro transcription amplification is a new template / primer-independent RNA amplification technology, that is, in the presence of a T7 promoter, T7 RNA polymerase isothermally synthesizes RNA fragments in the 5′-3′ direction. T7 in vitro transcription amplification has the characteristics of high yield, high fidelity, flexible sequence design, fast enzyme kinetics, and no thermal cycler involved. It has been widely used in isothermal nucleic acid amplification and biosensing. Recently, single-molecule detection has become a powerful analytical technique for sensitive detection of various biomarkers (such as nucleic acids, proteases, and epigenetic changes), with the advantages of low sample loss and high signal-to-noise ratio.

[0004] Traditional methods for ALP detection include colorimetry, electrochemical methods, surface enhanced resonance Raman scattering, and nuclear magnetic resonance / magnetic resonance imaging. Each of the above methods has its own characteristics, but usually involves complex nanomaterial preparation, cumbersome operations, special equipment, and time-consuming and labor-intensive procedures. In view of the advantages of simplicity, rapidity, and stability, fluorescence methods have been introduced into ALP detection methods, and they are mainly divided into two categories: based on fluorescent materials and based on small molecule fluorescent probes. Fluorescence methods based on fluorescent materials rely on carbon quantum dots, boron-doped graphene quantum dots, copper nanoparticles, and gold / silver nanoclusters; while fluorescence methods based on small molecule fluorescent probes include betaine-modified polyethyleneimine and two-photon fluorescent probes. However, in these methods, the fluorescence signal is affected by many factors (such as excitation, photobleaching, and emission collection). In addition, all of the above ALP methods rely on the dephosphorylation of small molecule substrates, and do not involve signal amplification mediated by cyclic nucleic acid replication. In order to improve the sensitivity, a dephosphorylation-mediated molecular beacon dendrimer nanostructured self-assembly was constructed with 5′-phosphate DNA chains as macromolecular substrates for one-step detection of ALP. However, the synthesis cost of molecular beacons is high and the assembly process takes a long time. Summary of the invention

[0005] In view of the problems existing in the above-mentioned prior art, the present invention constructs an end-repair-driven secondary in vitro transcription machine for single-molecule detection of alkaline phosphatase levels in human cancer. Based on the high specificity of ALP catalytic dephosphorylation, the high amplification efficiency of in vitro secondary transcription cascade and the high signal-to-noise ratio of single-molecule detection, the detection limit of ALP by this method can reach 7.93×10 -8 U / μL and 1 cell in vivo. In addition, it can be used to evaluate kinetic parameters, screen potential inhibitors and quantify ALP levels in complex biological samples such as various cancer cells and human serum. Importantly, this method can be performed isothermally and rapidly in one test tube without any cumbersome procedures, complex synthesis and high sample consumption.

[0006] The first objective of the present invention is to provide an end-repair driven secondary in vitro transcription machine for single molecule detection of alkaline phosphatase levels in human cancers, which can be further applied to determine the expression level of ALP in different cancer cells, providing a simple and powerful platform for ALP-related biomedical research and anticancer drug discovery.

[0007] In order to solve the above technical problems, the technical solution of the present invention is:

[0008] A method for preparing an end-repair driven secondary in vitro transcription machine, the specific steps of the method are as follows:

[0009] (1) HPLC-purified oligonucleotides HP1 and HP2 were synthesized by Sangon Biotechnology (Shanghai) Co., Ltd.;

[0010] The synthesized oligonucleotides HP1 and HP2 were diluted with 1× Tris-EDTA buffer to prepare 10 mM HP1 stock solution and 10 mM HP2 stock solution;

[0011] 10 mM of the above HP1 stock solution and 10 mM of the above HP2 stock solution were incubated in a hybridization buffer at 95° C. for 5 min, respectively, and then cooled to 25° C. to form a perfect hairpin structure, ie, HP1 solution and HP2 solution.

[0012] (2) Preparation of ALP-buffer: The concentrations of ALP-buffer were 0.1 U / μL, 0.01 U / μL, 0.001 U / μL, 10 -4 U / μL, 10 -5 U / μL, 5×10 -6 U / μL, 10 -6 U / μL, 5×10 -7 U / μL, 10 -7 U / μL of ALP solution was mixed with 0.5 μL of 10× CutSmart buffer;

[0013] 150nM HP1 solution obtained in step (1) was added to 5μL of the above ALP-buffer, and then incubated at 37°C for 30min to remove the 3′-PO4 group in HP1 catalyzed by ALP. The CutSmart buffer is a solution composed of 100mM magnesium acetate (Mg(AC)2), 500mM potassium acetate (KAC), 200mM tris-AC, and 1mg / mL bovine serum albumin (BSA, pH 7.9).

[0014] (3) To the dephosphorylated product obtained in step (2), 1.2 μl of 10 μM HP2 solution, 1 μl of 10 μM signal probe, 1 μl of 50 U / μL T7 RNA polymerase, 0.5 μl of 40 U / μL Taq DNA ligase, 0.7 μl of 1 U / μL DSN, 0.5 μl of 40 U / μL RNase, 0.8 μl of 25 mM NTPs, 2 μl of 10× RNAPol buffer, 2 μl of 10× Taq DNA ligase reaction buffer and 2 μl of 10× DSN buffer, 3.3 μl of DEPC were added in sequence, and then incubated at 37°C for 60 min to carry out the end repair-driven secondary in vitro transcription machinery and release the FAM fluorophore.

[0015] In one embodiment of the present invention, step (3) is, after dephosphorylation, adding the resulting product to 15 μL of reaction mixture (600 nM HP2, 500 nM signal probe, 50 U T7 RNA polymerase, 20 U Taq DNA ligase, 0.7 U DSN, 20 U RNase, 500 μM NTPs, 2 μL 10× RNAPol reaction buffer, 2 μL 10× Taq DNA ligase reaction buffer and 2 μL 10× DSN buffer), and then incubating at 37°C for 60 min to perform end repair driven secondary in vitro transcription machinery to release FAM fluorophore. RNAPol reaction buffer is the reaction buffer provided in the T7 RNA polymerase product. Taq DNA ligase is a thermostable ligase that can catalyze the formation of phosphodiester bonds between the 5′-phosphate end and the 3′-hydroxyl end of two adjacent DNA chains. Taq DNA ligase reaction buffer is the reaction buffer provided in the Taq DNA ligase product. DSN is double-strand specific nuclease (DSN) is an enzyme purified from the hepatopancreas of red king crab. DSN cuts DNA in DNA-RNA hybrid duplexes and can distinguish between short DNA duplexes that are fully matched and incompletely matched. DSN buffer is a reaction buffer for DSN that is self-configured according to the product instructions. RNase inhibitors specifically inhibit the activity of RNaseA, B and C, protect RNA under various reaction conditions, and can be used for in vitro inhibition of ribonucleases, including cDNA synthesis, RT-PCR, and in vitro transcription and translation procedures. NTPs are equimolar buffer solutions of ribonucleotide triphosphates (rATP, rCTP, rGTP and rUTP).

[0016] In one embodiment of the present invention, the RNAPol reaction buffer is the reaction buffer that comes with the T7 RNA polymerase product. The RNAPol buffer includes 400mM Tris-HCl, 60mM MgCl2, 20mM spermidine, 100mM dithiothreitol (DTT), pH = 7.9. In one embodiment of the present invention, the DSN buffer composition is 500mM Tris-HCl, 50mM MgCl2, 10mM DTT, pH = 8.0. The Taq DNA ligase buffer includes 200mM Tris-HCl, 250mM KAC, 100mM Mg(AC)2, 10mM NAD 1, 100mM DTT, 1% triton X-100, pH = 7.3.

[0017] The invention provides a kit for detecting alkaline phosphatase by secondary in vitro transcription driven by end repair.

[0018] The present invention provides an application of the above-mentioned secondary in vitro transcription machine or kit in single-molecule detection of alkaline phosphatase levels in human cancers, which is aimed at non-disease diagnosis and treatment.

[0019] The present invention is based on an end-repair-driven secondary in vitro transcription machinery for single-molecule detection of alkaline phosphatase levels in human cancer, with a minimum detection limit of 7.93×10 -8 U / μL.

[0020] The hybridization buffer includes 1.5mM MgCl2, 10mM Tris-HCl, pH 8.0; the RNAPol buffer includes 400mM Tris-HCl, 60mM MgCl2, 20mM spermidine, 100mM DTT, pH 7.9; the DSN buffer composition is 500mM Tris-HCl, 50mM MgCl2, and 10mM DTT, pH 8.0; the Taq DNA ligase buffer includes 200mM Tris-HCl, 250mM KAC, 100mM Mg(AC)2, 10mM NAD 1, 100mM DTT, 1% triton X-100, pH 7.3.

[0021] The end-repair driven secondary in vitro transcription machine is used for single molecule detection of alkaline phosphatase levels in human cancer, characterized in that the method is applied to sensitively detect ALP with a minimum detection limit of 7.93×10 -8 U / μL. Sensitivity is higher than that obtained by ratiometric fluorescence method (1×10 –4 U / μL) was 1261.0 times higher than that obtained by fluorescence method based on aggregation, 12.6 times higher than that obtained by fluorescence method based on molecular beacon dendritic nanoassembly (3.2×10 –7 U / μL) was 4.03 times higher than that obtained by the fluorescence method based on gold nanoclusters (1.6×10 –7 U / μL) equivalent.

[0022] The present invention also provides a biosensor for detecting alkaline phosphatase levels in human cancers, the biosensor comprising: a hairpin probe 1 (HP1), a hairpin probe 2 (HP2), a signal probe, T7 RNA polymerase, Taq DNA ligase, DSN, NTPs, and RNase; the hairpin probe 1 (HP1) and a sample solution are mixed to remove the 3′-PO4 group in HP1 catalyzed by ALP, and after dephosphorylation, the hairpin probe 2 (HP2), the signal probe, T7 RNA polymerase, Taq DNA ligase, DSN, NTPs, and RNase are sequentially added for incubation, and the alkaline phosphatase level in the sample is detected;

[0023] The HP1 sequence is: 5′-CTG TTC GTG TTT TAC TTG CCT GTG AAG TTT TTT TTT CTTCACAGG CAAGT-P-3′;

[0024] The HP2 sequence is: 5′-P-AAAACA CGAACA GGC AAC CAA CCC TATAGT GAG TCGTATTAT TTT TTAATACGACTC ACTATAGGG-3′;

[0025] The probe signal probe sequence is: 5′-BHQ1-AAG TAAAACACGAACAGG CAAC-FAM-3′;

[0026] In the hairpin probes HP1 and HP2, “P” indicates modification with a phosphate group; in the signal probe, the 3′ and 5′ ends were modified with FAM and BHQ1, respectively.

[0027] In one embodiment of the present invention, the hairpin probe 1 (HP1) and the hairpin probe 2 (HP2) are added at a concentration ratio of 1:4.

[0028] In one embodiment of the present invention, the added concentration of the signal probe is 500 nM, the added amount of T7 RNA polymerase is 50 U, the added amount of Taq DNA ligase is 20 U, the added amount of DSN is 0.7 U, the added amount of NTPs is 500 μM, and the added amount of RNase is 20 U.

[0029] The present invention also provides a method for detecting alkaline phosphatase using the above biosensor for non-diagnostic purposes, the method comprising the following steps:

[0030] (1) incubating the sample solution and the hairpin probe 1 (HP1) to remove the 3′-PO4 group in HP1 catalyzed by ALP;

[0031] (2) After dephosphorylation, the hairpin probe 2 (HP2), the signal probe, T7 RNA polymerase, Taq DNA ligase, DSN, NTPs, and RNase are added in sequence for incubation, and then the alkaline phosphatase level in the sample is detected.

[0032] In one embodiment of the present invention, the incubation conditions in step (1) are: incubation at 37° C. for 60 min.

[0033] In one embodiment of the present invention, the concentration ratio of the hairpin probe 1 (HP1) and the hairpin probe 2 (HP2) is 1:4; the added concentration of the signal probe is 500 nM, the added amount of T7 RNA polymerase is 50 U, the added amount of Taq DNA ligase is 20 U, the added amount of DSN is 0.7 U, the added amount of NTPs is 500 μM, and the added amount of RNase is 20 U.

[0034] In one embodiment of the present invention, in step (1), the sample solution is obtained by mixing the sample with 10×CutSmart buffer; the amount of the 10×CutSmart buffer added is 2 μL.

[0035] In one embodiment of the present invention, step (2) further includes 10×RNAPol buffer, 10×Taq DNA ligase reaction buffer, 10×DSN buffer, and DEPC; preferably, the amount of the 10×RNAPol buffer added is 2 μL; the amount of the 10×Taq DNA ligase reaction buffer added is 2 μL; the amount of the 10×DSN buffer added is 2 μL; and the amount of DEPC added is 3.3 μL.

[0036] The present invention also provides the use of the biosensor in preparing a kit for detecting the level of alkaline phosphatase.

[0037] The present invention also provides the use of the above biosensor or the above detection method in detecting the level of alkaline phosphatase, wherein the purpose of the application is non-disease diagnosis and treatment.

[0038] Beneficial Effects

[0039] Based on the high specificity of ALP-catalyzed dephosphorylation, the high amplification efficiency of the secondary in vitro transcription cascade, and the high signal-to-noise ratio of single-molecule detection, this method exhibits good specificity and ultra-high sensitivity. Importantly, it can be used to evaluate kinetic parameters, screen potential inhibitors, and even quantify ALP levels in various cancer cells and human serum. Its obvious advantages are as follows: (1) 5′-phosphate nucleotides are selected as macromolecular substrates to convert target signals into amplified RNA transcription signals;

[0040] (2) The high specificity of ALP-catalyzed dephosphorylation and T7 transcription amplification endows this method with high selectivity;

[0041] (3) The high amplification efficiency of the secondary in vitro transcription cascade gives this method a high sensitivity, with the lowest in vitro detection limit as low as 7.93×10 -8 U / μL, the in vivo detection limit can be as low as 1 cell;

[0042] (4) High signal-to-noise ratio of single-molecule detection, giving this method an ultra-low background signal;

[0043] (5) This method can be carried out isothermally and rapidly in a test tube without the need for cumbersome procedures, complex synthesis, and high sample consumption, which greatly simplifies the experimental procedure and has application prospects in phosphatase-related biomedical research, clinical diagnosis, and anticancer drug development. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 : Schematic diagram of the principle of end-repair-driven secondary in vitro transcription machinery for single-molecule detection of alkaline phosphatase levels in human cancers.

[0045] Figure 2 :(A) Gel electrophoresis verification of the adjacent ligation products of ALP-catalyzed HP1 and HP2; (B) Fluorescence measurement of the secondary in vitro transcription machinery in the absence (black) and presence (red) of ALP. Inset: Corresponding FAM fluorescence intensity at 488 nm (t-test, P<0.001). In (A) and (B), the concentrations of ALP, HP1, and HP2 were 0.1 U / μL, 150 nM, and 200 nM, respectively.

[0046] Figure 3 : Single-molecule images in the absence (A) and presence (B) of ALP. Scale bar is 5 μm. (C) Point spread function of FAM spots in single-molecule images. (D) Fluorescence intensity trajectory of FAM spots over time. The concentration of ALP is 0.1 U / μL.

[0047] Figure 4 :(A) Changes in FAM counts with ALP concentration. Inset: Linear correlation between FAM counts and the logarithm of ALP concentration. (B) Changes in FAM counts in the presence of control, 0.1U / μLUDG, 100mg / L BSA, 100mg / L FTO, 0.1U / μLM.SssI, and 0.1U / μLALP. Inset: Corresponding radar plots of FAM counts generated from the same samples above (t-test, P<0.001).

[0048] Figure 5 :(A) Variation of initial V with HP1 concentration. (B) Variation of relative activity of ALP with Na3VO4 concentration. Inset: Chemical structure of Na3VO4.

[0049] Figure 6:(A) Flow chart of the analysis of ALP levels in various human cancer cells. (B) FAM counts produced by HeLa cells, MCF-7 cells, HEK293 cells and controls in the presence and absence of Na3VO4 (t-test, P<0.001). The number of cells in the experiment was 10,000. The concentration of Na3VO4 was 100 μM. (C) Figure 5 Heat map analysis of ALP levels in B. (D) Changes of FAM counts with HeLa cell number. Inset: Linear correlation between FAM counts and the logarithm of HeLa cell number. DETAILED DESCRIPTION

[0050] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are embodiments of a part of the present invention, rather than all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0051] The principle of the present invention (such as Figure 1), two hairpin probes (i.e., HP1 and HP2) were strategically designed, with each stem containing two complementary strands (i.e., sense strand and antisense strand). In HP1, its 5′ and 3′ ends were modified with hydroxyl (OH) and phosphate (PO4) groups, respectively, and the embedded sensing strand of the stem was not only a DNA substrate for ALP but also a partial template for transcription. In HP2, its 5′ and 3′ ends were modified with PO4 groups and OH groups, respectively, the sensing strand of the stem was a T7 promoter sequence, and the protruding antisense strand of the stem was another partial template for transcription. The signal probe was designed as a 22nt linear DNA sequence modified with a quencher (BHQ1) and a fluorophore (FAM) at the 5' and 3' ends, respectively. The assay consists of three steps: (1) ALP catalyzes the removal of the 3′-PO4 group in HP1 to form a 3′-OH terminus, (2) a secondary in vitro transcription cascade driven by 3′ terminus dephosphorylation to release the FAM fluorophore, and (3) single-molecule counting of the released FAM fluorophore. In the presence of alkaline phosphatase, the 3′-PO4 group in HP1 is hydrolyzed to produce a 3′-OH terminus. Using the antisense strand of HP1 as a template, the 3′-hydroxylated HP1 and HP2 are ligated together so that the 3′-OH and 5′-PO4 are in close proximity. Under the catalysis of Taq ligase, proximity ligation is initiated to connect HP1 and HP2 to form a complete transcription template. By adding T7 RNA polymerase and NTPs, T7 RNA polymerase specifically binds to the T7 promoter region in HP2, activates in vitro transcription at the start point (i.e., 5′-GGGG-3′), and synthesizes a 37nt single-stranded (ss) RNA transcript (i.e., reporter probe). It is worth noting that through the repeated binding of T7 RNA polymerase to the T7 promoter region, efficient transcription can be carried out continuously to produce a large number of reporter probes. The reporter probe thus generated combines with the signal probe to form an RNA / DNA heteroduplex, which can serve as a substrate for double-stranded specific nuclease (DSN). DSN specifically degrades the DNA strand in the RNA / DNA heteroduplex, resulting in the release of the FAM fluorophore and the reporter probe at the same time. The released reporter probes in turn bind to the free signal probes, initiating multiple degradation-release hybridization cycles that ultimately release a large number of FAM fluorophores that can be simply counted by single-molecule detection. In contrast, in the absence of ALP, the 3′-PO4 group cannot be hydrolyzed to the 3′-OH group and therefore cannot initiate the secondary in vitro transcription cascade. Therefore, no signal probe can be degraded and no FAM fluorophore can be detected. Taking advantage of the high specificity of ALP-catalyzed dephosphorylation, the high efficiency of the secondary in vitro transcription cascade, and the high signal-to-noise ratio of single-molecule detection, the machine can specifically and sensitively detect ALP in human cancers at the single-molecule level.

[0052] The reagents and materials involved in the following examples are as follows:

[0053] All HPLC-purified oligonucleotides were synthesized by Sangon Biotechnology (Shanghai) Co., Ltd. Alkaline phosphatase (ALP), 10× CutSmart buffer (100 mM magnesium acetate (Mg(AC)2), 500 mM potassium acetate (KAC), 200 mM tris-AC, 1 mg / mL bovine serum albumin (BSA, pH = 7.9), T7 RNA polymerase, 10× RNAPol reaction buffer (400 mM tris-HCl, 60 mM MgCl2, 20 mM spermidine, 100 mM DTT, pH = 7.9), RNase inhibitor, ribonucleotide solution set (i.e., ATP, UTP, GTP, and CTP), uracil DNA glycosidase (UDG), and CpG methyltransferase (MSssI) were purchased from New England Biolabs (Beverly, MA, USA). Fat mass and obesity-associated protein (FTO) was obtained from ActiveMotif (Carlsbad, CA, USA). Double-stranded specific nuclease (DSN) and 10× DSN master buffer (500 mM Tris-HCl, 50 mM MgCl2, and 10 mM DTT, pH = 8.0) were obtained from Evrogen Joint Stock Company (Moscow, Russia). Na3VO4 and BSA were obtained from Sigma-Aldrich (St. Louis, MO, USA). RNase, diethylpyrocarbonate (DEPC)-treated water, and nuclear and cytoplasmic protein extraction kits were obtained from Sangon Biotechnology (Shanghai) Co., Ltd. Freshly prepared 1× Tris-EDTA buffer (10 mM Tris, 1 mM EDTA, pH = 8.0), 1× hybridization buffer (1.5 mM MgCl2, 10 mM Tris-HCl, pH = 8.0). Human cervical cancer cell line (HeLa cells), human breast adenocarcinoma cell line (MCF-7 cells) and human embryonic kidney cell line (HEK293 cells) were purchased from the Cell Bank of Shanghai Institute of Biological Sciences, Chinese Academy of Sciences (Shanghai, China). Ultrapure water was obtained from Millipore filtration system (Milford, MA, USA) and used in all experiments. FBS (fetal bovine serum) was purchased from Lanzhou Minhai Bioengineering Co., Ltd. (Lanzhou, China). DMEM medium and trypsin were purchased from Shanghai Yuanpei Biotechnology Co., Ltd. (Shanghai, China). SYBR Gold was purchased from Thermo Fisher Scientific (Shanghai, China).

[0054] The buffer components involved in the following examples are as follows:

[0055] 1× Tris-EDTA buffer, used for dilution and storage of oligonucleotides, includes 10 mM Tris, 1 mM EDTA, pH=8.0.

[0056] The hybridization buffer is a buffer used for forming a hairpin structure, including 1.5 mM MgCl2, 10 mM Tris-HCl, pH=8.0.

[0057] RNAPol reaction buffer is the reaction buffer provided in the T7 RNA polymerase product, including 400mM Tris-HCl, 60mM MgCl2, 20mM spermidine, 100mM DTT, pH=7.9;

[0058] Taq DNA ligase reaction buffer is the reaction buffer provided in the Taq DNA ligase product, including 200 mM Tris-HCl, 250 mM KAC, 100 mM Mg(AC)2, 10 mM NAD 1, 100 mM DTT, 1% triton X-100, pH = 7.3;

[0059] DSN buffer is a DSN reaction buffer prepared according to the product instructions, with the composition of 500mM Tris-HCl, 50mM MgCl2, 10mM DTT, pH=8.0;

[0060] Technical terms:

[0061] HP1 and HP2 are deoxyribonucleic acids that form a hairpin structure; in the hairpin probes HP1 and HP2, "P" represents a phosphate group modification.

[0062] T7 RNA polymerase is a DNA-dependent RNA polymerase that is highly specific for the T7 bacteriophage promoter;

[0063] Taq DNA ligase is a thermostable ligase that catalyzes the formation of phosphodiester bonds between the 5′-phosphate and 3′-hydroxyl ends of two adjacent DNA strands;

[0064] DSN is double-strand specific nuclease (DSN) is an enzyme purified from the hepatopancreas of red king crab. DSN cleaves DNA in DNA-RNA hybrid duplexes and can distinguish between perfect matching and imperfect matching short DNA duplexes.

[0065] The RNase inhibitor specifically inhibits the activity of RNaseA, B and C, protects RNA under various reaction conditions, and can be used for in vitro inhibition of ribonucleases, including cDNA synthesis, RT-PCR, and in vitro transcription and translation procedures;

[0066] The NTPs are equimolar buffered solutions of ribonucleotide triphosphates (rATP, rCTP, rGTP, and rUTP).

[0067] The methods and parameters for single molecule detection, inhibition effect testing and actual sample measurement involved in the following examples are as follows:

[0068] The resulting product was diluted 4000 times using imaging buffer (0.4% (w / v) D-glucose, 1 mg / mL glucose oxidase, 50 μg / mL BSA, 67 mM glycine–KOH, 0.04% mg / mL catalase, 2.5 mM MgCl2, and 1 mg / mL trolox, pH 9.4). The diluted solution was directly dropped on a coverslip and imaged by a TIRF system equipped with a 488 nm laser (50 mW, Coherent, USA) and a 100× objective lens (Olympus, Japan). Single-molecule images were acquired by an Andor Ixon DU897 EMCCD with an exposure time of 500 ms. A 400 × 400 pixel area was used for single-molecule counting. To monitor single-molecule photobleaching, the reaction mixture was continuously excited and 30 images were recorded with an exposure time of 400 ms. Images were analyzed by using ImageJ software.

[0069] The cell number determination and cell extract preparation methods involved in the following examples are as follows:

[0070] (1) According to the procedures in the manual, human cervical cancer cell line (HeLa cells), human breast cancer cell line (MCF-7 cells) and human embryonic kidney cell line (HEK293 cells) were cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin at a reaction temperature of 37°C in an incubator containing 5% CO2.

[0071] (2) In the exponential growth phase, cancer cells were collected by digestion with 500 μL 2.5 g / L trypsin, and the cell number was determined using an automatic cell counter IC1000 (Countstar, Shanghai, China).

[0072] (3) Cell extracts were obtained by using a nuclear and cytoplasmic protein extraction kit (Sangon Biotech) (Shanghai, China).

[0073] The present invention demonstrates an end-repair-driven secondary in vitro transcription machinery for single-molecule detection of alkaline phosphatase levels in human cancer. Based on the high specificity of ALP-catalyzed dephosphorylation, the high amplification efficiency of the in vitro secondary transcription cascade, and the high signal-to-noise ratio of single-molecule detection, the detection limit of ALP can reach 7.93×10 -8U / μL and 1 cell in vivo. In addition, it can be used to evaluate kinetic parameters, screen potential inhibitors and quantify ALP levels in complex biological samples such as various cancer cells and human serum. Importantly, this method can be isothermally and rapidly implemented in one test tube without any cumbersome procedures, complex synthesis and high sample consumption, and has great potential in the early diagnosis and monitoring of various diseases.

[0074] Example 1: Preparation of an end-repair driven secondary in vitro transcription machine

[0075] The specific implementation steps are as follows:

[0076] (1) HPLC-purified oligonucleotides HP1 and HP2 were synthesized by Sangon Biotechnology (Shanghai) Co., Ltd.;

[0077] The above-synthesized oligonucleotides HP1 and HP2 were diluted with 1× Tris-EDTA buffer to prepare 10 μM HP1 stock solution and 10 μM HP2 stock solution:

[0078] 10 μM HP1 stock solution and 10 μM HP2 stock solution were incubated in a hybridization buffer at 95° C. for 5 min, respectively, and then cooled to 25° C. to form a perfect hairpin structure, namely, HP1 solution and HP2 solution were obtained, respectively.

[0079] The HP1 sequence is: 5′-CTG TTC GTG TTT TAC TTG CCT GTG AAG TTT TTT TTT CTTCACAGG CAAGT-P-3′;

[0080] The HP2 sequence is: 5′-P-AAAACA CGAACA GGC AAC CAA CCC TATAGT GAG TCGTATTAT TTT T TAATACGACTC ACTATAGGG -3′;

[0081] (2) Preparation of ALP-buffer: ALP was mixed with 0.5 μL of 10× CutSmart buffer;

[0082] The final concentrations were: 0.1U / μL, 0.01U / μL, 0.001U / μL, 1×10 -4 U / μL, 1×10 -5 U / μL, 5×10 -6 U / μL, 1×10 -6 U / μL, 5×10 -7 U / μL, 1×10 -7 U / μL of ALP solution;

[0083] 150 nM HP1 solution obtained in step (1) was added to 5 mL of the above ALP-buffer, and then incubated at 37° C. for 30 min to remove the 3′-PO4 group in HP1 catalyzed by ALP.

[0084] (3) To the dephosphorylated product obtained in step (2), 1.2 μl of 10 μM HP2 solution, 1 μl of 10 μM signal probe, 1 μl of 50 U / μL T7 RNA polymerase, 0.5 μl of 40 U / μL Taq DNA ligase, 0.7 μl of 1 U / μl DSN, 0.5 μl of 40 U / μL Rnase, 0.8 μl of 25 mM NTPs, 2 μl of 10× RNAPol buffer, 2 μl of 10× Taq DNA ligase reaction buffer and 2 μl of 10× DSN buffer, and 3.3 μl DEPC were added in sequence, and then the above system was incubated at 37°C for 60 min to carry out the end repair-driven secondary in vitro transcription machinery and release the FAM fluorophore.

[0085] The signal probe sequence of the probe is: 5′-BHQ1-AAG TAA AAC ACG AAC AGG CAA C-FAM-3′, and the 3′ and 5′ ends are modified with FAM and BHQ1, respectively. The processing method of the signal probe is:

[0086] The synthesized probe signal was diluted with 1× Tris-EDTA buffer to prepare a 10 μM probe signal stock solution.

[0087] Example 2: Feasibility of verification experiment

[0088] 1. The specific implementation method is the same as Example 1, except that the final concentration of the ALP solution in step (2) is adjusted to 0.1 U / μL; at the same time, 10×CutSmart buffer without ALP is used as a control;

[0089] And, adjust step (3) to:

[0090] To the dephosphorylated product obtained in step (2), 0.4 μL of 10 μM HP2, 0.5 μL of 40 U / μL Taq DNA ligase, 2 μL of 10× Taq DNA ligase reaction buffer, and 2.1 μL DEPC were added to obtain a mixture;

[0091] The mixture was incubated at 37°C for 60 min to obtain a ligation product;

[0092] The ligation product was identified by using 12% denaturing PAGE with SYBR Gold as an indicator. The method is as follows: the ligation product was analyzed by electrophoresis on 12% non-denaturing polyacrylamide gel (PAGE) in 1×TBE buffer (9mM Tris-HCl, 9mM boric acid, 0.2mM EDTA, pH 7.9) at a constant voltage of 110V.

[0093] The gel was imaged using a Bio-Rad imaging system (Hercules, CA, USA). Figure 2 As shown in A.

[0094] The results show:

[0095] (1) Figure 2 As shown in A in Figure 1, in the presence of ALP, only one characteristic band of 116 nt was obtained ( Figure 1 A in Figure 4, lane 4), which is exactly the size of the ligation product (i.e., HP1-HP2 116 nt), indicating that ALP can hydrolyze 3′-PO4 to 3′-OH, inducing adjacent ligation to form an HP1-HP2 duplex (116 nt).

[0096] (2) In the absence of ALP, two separate bands of 50 nt and 66 nt were detected ( Figure 2 A, lane 5), which is the same size as the synthetic HP1 and HP2 ( Figure 2 A, lanes 1, 2, and 3), which means that when ALP is absent, it cannot induce dephosphorylation of the 3′ end of HP1, resulting in the inability of HP1 and HP2 to connect.

[0097] 2. To further verify the feasibility of this method, T7 RNA polymerase, signal probe and DSN were added to the above reaction mixture, and then the fluorescence emission spectrum was measured.

[0098] The specific steps are as follows:

[0099] To the ligation product prepared in step 1, 1 μl of 10 μM signal probe (processed according to the method of Example 1), 1 μl of 50 U / μL T7 RNA polymerase, 0.7 μL of 1 U / μL DSN, 0.5 μL of 40 U / μL Rnase, 0.8 μL of 25 mM NTPs, 2 μL of 10× RNAPol buffer, 2 μL of 10× DSN buffer and 3 μL of DEPC were added. The above system was then incubated at 37°C for 60 min, and then the fluorescence emission spectrum was measured; the results are as follows: Figure 2 shown.

[0100] The results show:

[0101] In the presence of ALP, a significant FAM fluorescence signal with a characteristic 488 nm emission peak was observed ( Figure 2 B, red curve and inset, red bars), indicating that 3′ dephosphorylation of ALP can activate T7 in vitro transcription, generating a large amount of reporter probe, which can bind to the signal probe and induce DSN-mediated cyclic release of FAM fluorophore.

[0102] In contrast, in the absence of ALP, only very low FAM fluorescence signals were observed ( Figure 2 B, black curve and inset, black column), indicating that in the absence of ALP, dephosphorylation cannot occur and induce a secondary in vitro transcription cascade. These results indicate that this method can specifically and sensitively detect ALP.

[0103] Example 3: Single molecule detection of ALP

[0104] The specific implementation method is the same as Example 1, except that the final concentration of the ALP solution in step (2) is adjusted to 0.1 U / μL; at the same time, 10×CutSmart buffer without ALP is used as a control; and the final product is subjected to single molecule detection. Figure 3 shown.

[0105] The results show:

[0106] (1) Figure 3 As shown in A, no FAM counts were observed in the control without ALP, which means that no secondary in vitro transcription cascade occurred and no FAM molecules were released into the solution.

[0107] (2) In the presence of ALP, a large number of FAM counts were detected ( Figure 3 B), indicating that ALP can activate the end-repair-driven secondary in vitro transcription machinery, releasing a large number of FAM molecules into the solution.

[0108] (3) In addition, the point spread functions (PSFs) of the FAM fluorescence spots indicate the high signal-to-noise ratio of the machine ( Figure 3 C), and the one-step photobleaching behavior of the FAM spots indicated that each fluorescent spot had one FAM molecule ( Figure 3 These results demonstrate that this method is suitable for single-molecule detection of ALP.

[0109] Example 4: Sensitivity Detection

[0110] The specific steps for optimizing the conditions are as follows:

[0111] The specific implementation method is the same as Example 1, except that the final concentration of the ALP solution in step (2) is adjusted to: 0.1U / μL, 0.01U / μL, 0.001U / μL, 10 -4 U / μL, 10 -5 U / μL, 5×10 -6 U / μL, 10 -6 U / μL, 5×10 -7 U / μL, 10 -7 U / μL; at the same time, adjust the concentration ratio of HP1 and HP2, the amount of T7 RNA polymerase, the amount of DSN enzyme, the concentration of the signal probe, and the time of in vitro transcription; the specific steps are as follows:

[0112] 1. The amount of 1.2 μl of 10 μM HP2 in step (3) was adjusted to 0.3 μL, 0.6 μL, 0.9 μL, 1.2 μL, and 1.5 μL, respectively, so that the ratio of HP1 to HP2 was 1:1, 1:2, 1:3, 1:4, and 1:5, respectively.

[0113] The results showed that the FAM fluorescence intensity increased with the increase of the HP1:HP2 ratio and reached the maximum value at 1:4. The optimal concentration ratio of HP1 and HP2 was 1:4.

[0114] 2. Adjust the amount of 1 μl of 50U / μL T7 RNA polymerase in step (3) to 0.4 μL, 0.6 μL, 0.8 μL, 1 μL, and 1.2 μL, respectively.

[0115] The results showed that the FAM fluorescence intensity increased as the amount of T7 RNA polymerase increased from 30 U to 50 U, and decreased after exceeding 50 U. Therefore, 50 U was selected as the optimal amount of T7 RNA polymerase.

[0116] 3. The amount of 0.7 μL of DSN at a concentration of 1 U / μL in step (3) was adjusted to 0.5 μL, 0.6 μL, 0.7 μL, 0.8 μL, and 0.9 μL, respectively.

[0117] The results showed that the FAM fluorescence intensity increased as the amount of DSN increased from 0.4 to 0.7 U, and decreased after exceeding 0.7 U. Therefore, in subsequent studies, 0.7 U was selected as the optimal amount of DSN.

[0118] 4. The amount of 1 μl of the 10 μM signal probe in step (3) was adjusted to 0.4 μL, 0.6 μL, 0.8 μL, 1 μL, and 1.2 μL respectively.

[0119] The results showed that the FAM fluorescence intensity increased as the signal probe concentration increased from 200 nM to 600 nM and reached a plateau at 500 nM. Therefore, 500 nM was selected as the optimal concentration of the signal probe.

[0120] 5. Adjust the reaction time in step (3) (incubation at 37°C for 60 min) to 10 min, 20 min, 40 min, 60 min, and 80 min, respectively.

[0121] The results showed that the FAM fluorescence intensity gradually increased with the reaction time from 10 minutes to 80 minutes and reached stability at 60 minutes. Therefore, 60 minutes was selected as the optimal reaction time.

[0122] The results show:

[0123] Under the optimal reaction conditions, the FAM counts in response to different concentrations of ALP were analyzed ( Figure 4 As the ALP concentration increased from 1×10 -7 When the concentration of ALP increased to 0.1 U / μL, the FAM count (N) increased accordingly and showed a linear dependence on the logarithm of the ALP concentration (C). Figure 4 A).

[0124] The equation is N = 432.76 + 54.94log 10 C(R 2 =0.9940).

[0125] The detection limit was 7.93 × 10 -8 U / μL. Sensitivity is higher than that obtained by ratiometric fluorescence method (1×10 –4 U / μL) was 1261.0 times higher than that obtained by fluorescence method based on aggregation, 12.6 times higher than that obtained by fluorescence method based on molecular beacon dendritic nanoassembly (3.2×10 –7 U / μL) was 4.03 times higher than that obtained by the fluorescence method based on gold nanoclusters (1.6×10 –7 U / μL) equivalent.

[0126] The increased sensitivity is due to:

[0127] (1) High specificity of ALP-directed 3′-end dephosphorylation;

[0128] (2) High specificity and high amplification efficiency of the proximity ligation-dependent transcription cascade;

[0129] (3) High degradation efficiency of DSN on DNA in RNA / DNA heteroduplexes;

[0130] (4) Ultra-high signal-to-noise ratio for single-molecule counting.

[0131] Example 5: Specificity detection

[0132] Uracil glycosylase (UDG), bovine serum albumin (BSA), fat mass and obesity-associated protein (FTO), and CpG methyltransferase (MSssI) were used as negative controls. The specific steps are as follows:

[0133] The specific implementation method is the same as that of Example 1, except that the preparation of the ALP-buffer solution in step (2) is adjusted to the preparation of the UDG-buffer or the BSA-buffer or the FTO-buffer or the MSssI-buffer:

[0134] The solution was obtained by mixing 0.1U / μL UDG solution, BSA solution, FTO solution or CpG solution and 0.5μL 10×CutSmart buffer.

[0135] 150 nM HP1 solution obtained in step (1) was added to 5 mL of the above buffer, and then incubated at 37°C for 30 min;

[0136] Meanwhile, 10× CutSmart buffer without ALP was used as a control;

[0137] According to the method of Example 1, specific detection was performed.

[0138] The results are as follows Figure 4 As shown in B.

[0139] The results show:

[0140] Under the same conditions, in UDG( Figure 4 B in the yellow column), BSA ( Figure 4 B, blue column), FTO( Figure 4 B and green columns), M.SssI( Figure 4 The pink column in B) and the control without ALP ( Figure 4 In the presence of B (black column in Figure ), only very low FAM signal was obtained.

[0141] In contrast, in the presence of ALP, a significant FAM signal was generated ( Figure 4 The signals generated by UDG, BSA, FTO and M.SssI were 8.93, 9.35, 10.47 and 10.05 times higher than those generated by UDG, BSA, FTO and M.SssI, respectively (t-test, P<0.001).

[0142] This result was further confirmed by the radar plot, which showed that only ALP could catalyze the removal of the 3′-PO4 group from HP1, thereby initiating the secondary in vitro transcription machinery and releasing a large number of FAM molecules. These results indicate that the method has good selectivity for ALP even in the presence of nonspecific enzymes.

[0143] Example 6: Kinetic analysis and inhibition assay

[0144] 1. The product obtained in Example 1 was subjected to single molecule detection.

[0145] To evaluate whether this method could be used for enzyme kinetic analysis, the initial velocity (V) of the dephosphorylation reaction at 37°C for 6 min in the presence of 0.1 U / μL ALP was analyzed.

[0146] The HP1 concentrations in step (2) were set to 150 nM, 100 nM, 80 nM, 60 nM, 40 nM, 30 nM, and 10 nM, respectively;

[0147] Measure the initial velocity (V) at different HP1 concentrations and substitute the data into V = V max [S] / (K m +[S]) equation, where V max , K m and [S] are the maximum initial velocity, Michaelis–Menten constant and HP1 concentration, respectively.

[0148] The results are as follows Figure 5 As shown in A:

[0149] As the HP1 concentration increased from 0 to 160 nM, the initial V increased accordingly, and V max and K m The values ​​are 30.06min –1 and 62.66nM. The K m The value was consistent with the Km values ​​obtained by the dual transcription amplification-based fluorescence method (55.56 nM) and the molecular beacon-based dendrimer nanoassembly fluorescence method (80.6 nM), indicating that this method can accurately evaluate the kinetic parameters of ALP.

[0150] 2. Sodium orthovanadate (Na3VO4) was used as an ALP inhibitor to evaluate the inhibitory effect.

[0151] The specific implementation method is the same as that of Example 1, except that the preparation of the ALP-buffer in the adjustment step (2) is as follows:

[0152] Na3VO4 at concentrations of 10 μM, 30 μM, 50 μM, 70 μM, 90 μM, 110 μM, 130 μM, and 150 μM were pre-incubated with 0.5 μL 1U / μL ALP for 30 min at 37° C. The relative activity (RA) of ALP was determined based on the following equation:

[0153] RA(%)=Ci / Ct×100%=10 (Ni-Nt) / 54.94 ×100%

[0154] Where Ni is the FAM count in the presence of ALP+Na3VO4, and Nt is the FAM count in the presence of ALP alone.

[0155] The results are as follows Figure 5 B shows:

[0156] When the concentration of Na3VO4 increased from 10 μM to 150 μM, the relative activity (RA) of ALP showed a dose-dependent decrease ( Figure 5 B) IC 50 The concentration of Na3VO4 at which ALP activity decreased by 50% was measured to be 61.7 μM, which is comparable to the IC obtained by the single QD-based fluorescence method (87.69 μM) and the DNA walking-based fluorescence method (31.17 ± 2.34 μM). 50 These results indicate that this method can be used to screen ALP inhibitors.

[0157] Example 7: Actual sample analysis

[0158] In order to verify whether this method can be used for the analysis of real samples, HeLa, MCF-7 and HEK293 cells were used as models for the analysis of ALP levels in cells ( Figure 6 A).

[0159] The specific steps are as follows:

[0160] 1. Detection of ALP in cell extracts

[0161] (1) According to the procedures in the instructions, human cervical cancer cell line (HeLa cells), human breast cancer cell line (MCF-7 cells) and human embryonic kidney cell line (HEK293 cells) were cultured, and cell extracts were obtained using a nuclear and cytoplasmic protein extraction kit (Sangon Biotech) (Shanghai, China).

[0162] HeLa cell extracts, MCF-7 cell extracts, and HEK293 cell extracts were obtained respectively;

[0163] The preparation methods of HeLa cell extract solution, MCF-7 cell extract solution and HEK293 cell extract solution are as follows:

[0164] 1) The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in an incubator containing 5% carbon dioxide. The cell number was measured using a Countstar cell counter.

[0165] 2) Collect the cells by trypsin digestion, rinse once with 2 mL PBS, add 500 μL PBS, re-spin and transfer to a new centrifuge tube, centrifuge at 3350 rpm for 3 minutes, and then aspirate the supernatant to obtain compacted cells.

[0166] 3) Add 1 mL of Buffer A to the cells, vortex for 15 seconds, and let stand on ice for 15 minutes. Then add 11 μL of Buffer B, vortex for 5 seconds, and let stand on ice for 1 minute. Vortex again for 5 seconds, and centrifuge at 12,500 rpm for 5 minutes.

[0167] 4) Remove the supernatant and the lower liquid from the centrifuge tube, leaving the white nuclear precipitate in the middle layer, add 100 μL Buffer C, vortex for 10 seconds, place in a shaker ice bath for 40 minutes, and vortex again for 30 seconds. Then centrifuge the suspension at 12500 rpm for 5 minutes, and take the supernatant as the nuclear extract. Store in a -80℃ refrigerator.

[0168] The above-mentioned Buffer A, Buffer B, and Buffer C were all from the Nuclear and Cytoplasmic Protein Extraction Kit (Sangon Biotech) (Shanghai, China).

[0169] (2) The specific method is the same as Example 1, except that the preparation of ALP-buffer in step (2) is adjusted to the preparation of HeLa cell extract-buffer or MCF-7 cell extract-buffer or HEK293 cell extract-buffer:

[0170] The mixture was obtained by mixing 101.010 mg / mL of HeLa cell extract solution, 123.506 mg / mL of MCF-7 cell extract solution, or 39.501 mg / mL of HEK293 cell extract solution with 0.5 μL of 10× CutSmart buffer;

[0171] 150 nM HP1 solution obtained in step (1) was added to 5 mL of the above buffer, and then incubated at 37°C for 30 min;

[0172] The FAM signal was detected according to the method of Example 1.

[0173] The results are as follows Figure 6 As shown:

[0174] like Figure 6As shown in B, HeLa( Figure 6 B, red column), MCF-7( Figure 6 B, cyan columns) and HEK293 cells ( Figure 6 Different FAM signals were observed in B and green columns, which were much higher than those produced by the control ( Figure 6 (black column in B) (t-test, P<0.001). FAM counts decreased in the order of HeLa>MCF-7>HEK293, which means that the expression levels of ALP in different cancer cells are different.

[0175] 2. To further confirm that it was ALP rather than other enzymes that induced the FAM signal enhancement, Na3VO4 was used to inhibit ALP in the cells.

[0176] The specific method is the same as step 1, except that the preparation of the HeLa cell extract solution or the MCF-7 cell extract solution or the HEK293 cell extract solution is adjusted as follows:

[0177] 0.5 μL of 100 μM Na 3 VO 4 was added to 0.82 μL of HeLa cell extract solution, 1.42 μL of MCF-7 cell extract solution, and 0.57 μL of HEK293 cell extract solution, respectively.

[0178] The rest is the same as step 1.

[0179] The results are as follows Figure 6 As shown:

[0180] Compared with the control without Na3VO4 treatment, the FAM counts in HeLa cells induced by 100 μM Na3VO4 decreased by 75.0% ( Figure 6 In B, pink column), FAM counts in MCF-7 cells decreased by 44.1% ( Figure 6 In B, blue column), in HEK293 cells, FAM counts decreased by 41.9% ( Figure 6 B and yellow columns).

[0181] Under the same conditions, the heat map was further used to visualize the ALP level analysis. Figure 6 As shown in Figure C, HeLa, MCF-7, and HEK293 cells without Na3VO4 treatment produced high FAM signals, but HeLa, MCF-7, and HEK293 cells treated with Na3VO4 produced lower FAM signals, which is consistent with Figure 6 The results in B are consistent.

[0182] In addition, the FAM signal generated by different numbers of HeLa cells was measured. Figure 6As shown in D, when the number of HeLa cells increases from 0 to 10,000 cells, the FAM count increases and shows a linear dependence on the logarithm of the number of HeLa cells (from 1 to 10,000). The equation is N = 42.48 + 32.37log 10 X(R 2 =0.9900), where N is the FAM count and X is the number of HeLa cells. The detection limit was determined to be 1 cell.

[0183] Embodiment 8:

[0184] The specific implementation method is the same as that of Example 1, except that the sequence of the signal probe in Example 1 is replaced with 5′-BHQ1-AAG TAAAACACGAAC A-FAM-3′, and ALP is detected according to the method of Example 1.

[0185] Detection effect: The replaced signal probe does not produce significant fluorescence signal.

[0186] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A biosensor for detecting alkaline phosphatase levels in human cancer, characterized in that The sensor comprises: a hairpin probe 1 (HP1), a hairpin probe 2 (HP2), a signal probe, T7 RNA polymerase, Taq DNA ligase, DSN, NTPs, and RNase; the hairpin probe 1 (HP1) and a sample solution are mixed to remove the 3′-PO4 group in HP1 catalyzed by ALP, and after dephosphorylation, the hairpin probe 2 (HP2), the signal probe, T7 RNA polymerase, Taq DNA ligase, DSN, NTPs, and RNase are added for incubation, and the alkaline phosphatase level in the sample is detected; The hairpin probe 1 (HP1) sequence is: 5′-CTG TTC GTG TTT TAC TTG CCT GTGAAG TTT TTTTTT CTT CACAGG CAAGT-P-3′; The hairpin probe 2 (HP2) sequence is: 5′-P-AAAACACGAACAGGCAAC CAACCC TATAGT GAG TCGTAT TATTTT TTAATACGACTCACTATAGGG-3′; The signal probe sequence is: 5′-BHQ1-AAG TAAAACACGAACAGG CAAC-FAM-3′; In the hairpin probes HP1 and HP2, "P" indicates phosphate group modification; in the signal probe, the 3' and 5' ends are modified with FAM and BHQ1, respectively.

2. The biosensor according to claim 1, characterized in that The hairpin probe 1 (HP1) and the hairpin probe 2 (HP2) are added at a concentration ratio of 1:

4.

3. The biosensor according to claim 2, characterized in that The added amount of the signal probe is: 600nM, the added amount of the T7 RNA polymerase is: 50U, the added amount of the Taq DNA ligase is: 20U, the added amount of the DSN is: 0.7U, the added amount of the NTPs is: 500μM, and the added amount of the RNase is: 20U.

4. A method for detecting alkaline phosphatase using the biosensor according to any one of claims 1 to 3 for non-diagnostic purposes, characterized in that: The method comprises the following steps: (1) incubating the sample solution and the hairpin probe 1 (HP1) to remove the 3′-PO4 group in HP1 catalyzed by ALP; (2) after dephosphorylation, adding the hairpin probe 2 (HP2), the signal probe, T7 RNA polymerase, Taq DNA ligase, DSN, NTPs, and RNase for incubation, and then detecting the alkaline phosphatase level in the sample; The hairpin probe 1 (HP1) sequence is: 5′-CTG TTC GTG TTT TAC TTG CCT GTGAAG TTT TTTTTT CTT CACAGG CAAGT-P-3′; The hairpin probe 2 (HP2) sequence is: 5′-P-AAAACACGAACAGGCAAC CAACCC TATAGT GAG TCGTAT TATTTT TTAATACGACTCACTATAGGG-3′; The signal probe sequence is: 5′-BHQ1-AAG TAAAACACGAACAGG CAAC-FAM-3′; In hairpin probe 1 (HP1) and hairpin probe 2 (HP2), "P" indicates phosphate group modification; in the signal probe, the 3' end and 5' end are modified with FAM and BHQ1, respectively.

5. The detection method according to claim 4, characterized in that: Incubation conditions in step (1): incubate at 37°C for 60 min.

6. The detection method according to claim 5, characterized in that: The concentration ratio of the hairpin probe 1 (HP1) and the hairpin probe 2 (HP2) added is 1:4; the added concentration of the signal probe is 500 nM, the added amount of T7 RNA polymerase is 50 U, the added amount of Taq DNA ligase is 20 U, the added amount of DSN is 0.7 U, the added amount of NTPs is 500 μM, and the added amount of RNase is 20 U.

7. The detection method according to claim 6, characterized in that: In step (1), the sample solution is obtained by mixing the sample with 10×CutSmart buffer; the amount of the 10×CutSmart buffer added is 2 μL.

8. The detection method according to claim 7, characterized in that: Step (2) further includes 10×RNAPol buffer, 10×Taq DNA ligase reaction buffer, 10×DSN buffer, and DEPC; preferably, the amount of the 10×RNAPol buffer added is 2 μL; the amount of the 10×Taq DNA ligase reaction buffer added is 2 μL; the amount of the 10×DSN buffer added is 2 μL; and the amount of DEPC added is 3.3 μL.

9. Use of the biosensor according to any one of claims 1 to 3 in the preparation of a kit for detecting alkaline phosphatase levels.

10. Use of the biosensor according to any one of claims 1 to 3 or the detection method according to any one of claims 4 to 8 in detecting alkaline phosphatase levels, wherein the purpose of the use is non-disease diagnosis and treatment.